article thumbnail

Why Do Pharma Companies Outsource to CROs?

Vial

Pharmaceutical companies often face challenges in conducting clinical trials due to the need for substantial knowledge, time, and resources. To address these challenges, many companies outsource their clinical trials to contract research organizations (CROs) with established protocols, global reach, and therapeutic area expertise1.

article thumbnail

Four Ideas for Pharma to Maximize the Influence of Digital Opinion Leaders in Medicine

H1 Blog

Insights for Thought Leading Stakeholder Engagement to Decrease Medication Non-Adherence Pharmaceutical companies have long recognized the importance of engaging key opinion leaders (KOLs) to gain insight and support for clinical research, drug development, and medical education.

article thumbnail

Women in STEM with Kristina Torfgard

Drug Target Review

However, my goal was all the time to work with drug development in the pharma industry, so I moved on and started that journey in 1992 when I took on a role as Clinical Research Manager at AstraHässle, a mid-size Swedish pharma company. I experienced challenges in cultural differences working with US, UK, Japan, and China.

article thumbnail

Roche acquires Irish biotech firm Inflazome

The Pharma Data

Swiss pharma company to acquire biotech for $449m (€380m). Swiss pharma company Roche is set to acquire Irish biotech firm Inflazome for an upfront payment of $449m (€380m).

article thumbnail

Patient Partnership Index virtual conference to take place October 7

The Pharma Data

. Senior leaders in pharma and patient groups will be offering key insights into impactful patient centricity and advocacy at the Patient Partnership Index virtual conference on October 7. Places are limited, with priority being given to those working for pharmaceutical companies or patient groups.

article thumbnail

FDA Poised to Make Impact on Underrepresented Populations in Clinical Studies

H1 Blog

Hence, pharmaceutical companies need to start making preparations to ensure compliance with the new requirements. We’re curious to see what will happen over the next 12 months and how pharma companies will respond.” This is monumental, as most guidances do not include binding elements per legislation.

FDA 59
article thumbnail

Drug Repurposing: A New Life for Old Drugs

DrugBank

They also provide a level playing field for academics, biotech companies, and pharma giants to compete on. However, Pharma companies do have a some advantages when it comes to the proprietary data they have on failed or patented drugs, giving them a step ahead in exploring repurposing.

Drugs 72